MARCH 10, 2025

Tevimbra Approved for Some Patients With Unresectable or Metastatic ESCC


The FDA has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose programmed death ligand-1 (PD-L1) score is ≥1.